Every year, 72,680 people across the U.S. – or 199 people per day – receive a cancer diagnosis of the oral cavity, pharynx or ...

Low-dose computed tomography is more sensitive than chest radiography in diagnosing lung metastases of second primary lung cancer in HNSCC survivors.

Professor Reem Hanna will be speaking on photobiomodulation in mitigating adverse effects of head and neck cancer therapies. SIP SMART2 is a multi-centre pilot cluster-randomised trial of a tailored ...

April which is a Head neck cancer awareness month, let us all take a pledge to unite together in our fight against head neck cancers.

Speaking at a Buckingham Palace celebration of community-based initiatives raising cancer awareness and supporting those living with the disease, Charles said that "each diagnosis, each new case ...

Former The Real Housewives of Beverly Hills star Teddi Mellencamp recently reflected on her ongoing battle with cancer. The media personality took ... "Seeing my scars on my back and head make me cry ...

Presented at the American Association for Cancer Research (AACR25) Annual Meeting, the promising results from the Phase 3 KEYNOTE-689 trial suggest a potential breakthrough in the treatment of head ...

9-month-old Theo Johnson has a rare condition called Posterior Urethral Valves and is looking for a kidney for a transplant. Theo's Mother, Auburn, is unable to donate because she was diagnosed ...

AUGUSTA, Ga. (WJBF) – April is Head and Cancer Awareness Month, and the Georgia Cancer Center held free screenings Friday. It’s a process that takes a few minutes. But makes all the difference.

Previously, the drug has been approved in China for nasopharyngeal carcinoma, a rare cancer that develops in ... trial proves that ivonescimab’s head-to-head win against Keytruda as NSCLC ...

Head and Neck Cancer Awareness Month. Free screenings will occur from 8 a.m. to 12 p.m. at Prisma Health Baptist Hospital. The nationwide event is sponsored by the Head and Neck Cancer Alliance.

“While there were encouraging trends in ASPEN-03 in ORR versus the historical and internal control, we've decided not to pursue evorpacept and [Keytruda] in head and neck cancer in light of our ...